Immunovant, Inc. (IMVT) vs Praxis Precision Medicines, Inc. (PRAX)

Immunovant, Inc. and Praxis Precision Medicines, Inc. are both Biotechnology companies. Praxis Precision Medicines, Inc. is the larger, with a market value of $7.9B against $7.1B — 1.1× the size. Across the 10 metrics below, Praxis Precision Medicines, Inc. leads on 7 and Immunovant, Inc. on 3.

Valuation

Metric IMVT PRAX Biotechnology median
P/E n/m n/m 7.88
P/S n/m 956.32 11.47
P/B 9.31 6.10 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 867.63 10.73
Earnings yield (8.47%) (4.61%) (28.84%)
Free cash flow yield (6.06%) (3.74%) (23.03%)

Profitability

Metric IMVT PRAX Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (80.10%) (38.86%) (57.72%)
Return on assets (71.10%) (36.80%) (49.22%)
Return on invested capital 0.00% (40.58%) 0.00%

Growth

Metric IMVT PRAX Biotechnology median
Revenue growth (TTM) — 249.53% 5.64%
EPS growth (last fiscal year) (1.47%) (32.03%) —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMVT PRAX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.27 15.73 4.73
Net debt to EBITDA 1.69 1.82 0.96

Dividend

Metric IMVT PRAX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric IMVT PRAX Biotechnology median
Market cap 7.11b 7.87b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack